Director, AI/ML MIDD Oncology Clinical Pharmacology, Modeling and Simulation
Leads model-informed drug development for oncology programs, defining and executing model-based strategies from late discovery through lifecycle management. Conducts population PK, exposure-response, simulation-based trial design and dose selection, applying AI/ML, quantitative systems pharmacology and model-based meta-analysis. Presents to governance boards and regulators and works across matrix teams on small molecules, biologics and antibody drug conjugates.